E. coli strain engineering for the production of advanced biopharmaceutical products

Since the emergence of the biopharmaceutical industry in the 1980's, Escherichia coli, has played an important role in the industrial production of recombinant proteins and plasmid DNA for therapeutic use. Currently, advanced biopharmaceutical products, including rationally designed recombinant...

Full description

Saved in:
Bibliographic Details
Published in:FEMS microbiology letters 2018-08, Vol.365 (15)
Main Authors: Selas Castiñeiras, Tania, Williams, Steven G, Hitchcock, Antony G, Smith, Daniel C
Format: Article
Language:English
Subjects:
Biopharmaceuticals
E coli
Gene therapy
Industrial production
Microbiology
Plasmids
Proteins
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Since the emergence of the biopharmaceutical industry in the 1980's, Escherichia coli, has played an important role in the industrial production of recombinant proteins and plasmid DNA for therapeutic use. Currently, advanced biopharmaceutical products, including rationally designed recombinant proteins and viral-vector gene therapies, offer unprecedented promise for the long-term management, and even cure of disease. As such, E. coli remains an important production host for the biopharmaceutical industry. This review provides insight into the industrially relevant strain engineering approaches used to enhance both the quantity and quality of these therapeutic products.
ISSN:1574-6968
0378-1097
1574-6968
DOI:10.1093/femsle/fny162